Neurofilament Medium Chain (NF-M), also known as NEFM, is a neuronal intermediate filament protein encoded by the NEFM gene on chromosome 8p21, adjacent to the NEFL gene. NF-M co-assembles with NF-L and NF-H to form the heteropolymer neurofilament network in large-diameter axons .
NF-M plays a critical role in establishing and maintaining axonal caliber, which directly impacts nerve conduction velocity. It is one of the most phosphorylated neuronal proteins, with phosphorylation levels increasing during development and decreasing in certain disease states. NF-M is released into CSF and blood following axonal injury, serving as a biomarker for neurodegeneration .
¶ Domain Structure
NF-M has the typical intermediate filament domain organization:
¶ Head Domain (1-90)
- N-terminal non-helical domain
- Multiple serine phosphorylation sites
- Regulates filament assembly and interactions
¶ Central Rod Domain (91-424)
- Alpha-helical coiled-coil region
- Highly conserved across species
- Dimer formation site
- Contains repeat motifs
¶ Tail Domain (425-916)
- Long C-terminal tail domain (carries the M designation)
- Lysine-serine-proline (KSP) repeat motifs
- Extensive phosphorylation sites
- Projects from filament surface to regulate spacing
- Contains binding sites for other proteins
- NF-M co-polymerizes with NF-L to form heterodimers
- These dimerize to form tetramers, the building block of filaments
- NF-M determines the spacing between neurofilament side chains
- Critical for maintaining optimal axonal diameter
- Phosphorylation of tail domain regulates filament spacing
- Casein kinase II and MAP kinases are key kinases
- Phosphorylation increases during development
- Dephosphorylation facilitates transport
- Neurofilaments are transported bidirectionally along microtubules
- Phosphorylation state affects transport rates
- Kinesin and dynein motors move neurofilaments
- Proper transport is essential for axonal maintenance
- Forms heteropolymers with NF-L and NF-H
- Binds to protein 4.1 in the axonal membrane
- Associates with intermediate filament-associated proteins
- Interacts with signaling proteins via phosphorylated tails
- CSF NF-M elevated in ALS, PD, AD, and other neurodegenerative conditions
- Blood NF-M can be detected with sensitive assays
- Often measured alongside NF-L for comprehensive assessment
- Reflects the extent of axonal damage
- Neurofilament accumulation in swollen axons is a hallmark of many neurodegenerative diseases
- Abnormal phosphorylation patterns in disease states
- NF-M fragmentation detected in affected brain regions
- Mutations in NEFM cause axonal neuropathy
- Impaired axonal transport contributes to neurofilament accumulation
- Abnormal aggregation in axonal spheroids
- Seen in ALS, Charcot-Marie-Tooth disease, and experimental models
- NF-M as biomarker in clinical trials
- Targeting phosphorylation pathways to improve transport
- Gene therapy approaches for NEFM mutations
- NF-L and NF-M together provide more comprehensive axonal damage assessment
- Used in clinical trials for ALS, PD, and AD
- Helps monitor disease progression and treatment response
- Predictive of clinical outcomes
- Develop inhibitors of neurofilament-aggregating pathways
- Gene therapy for NEFM-linked neuropathies
- Small molecules to improve neurofilament phosphorylation dynamics
- Immunotherapy to reduce neurofilament levels
-
Nixon et al., Neurofilament expression in human brain and neurodegenerative disease (1994). Journal of Comparative Neurology. 1994;347(1):1-16.
-
Julien et al., Neurofilament proteins in neurodegeneration (1995). Progress in Brain Research. 1995;105:325-333.
-
Lee et al., Neurofilament phosphorylation in neuronal development and disease (2014). Experimental Neurology. 2014;253:71-81.